Detalles de la búsqueda
1.
Determinants of omalizumab dose-related efficacy in oral immunotherapy: Evidence from a cohort of 181 patients.
J Allergy Clin Immunol
; 147(1): 233-243, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32980425
2.
Economic considerations on the usage of biologics in the allergy clinic.
Allergy
; 76(1): 191-209, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32656802
3.
Children with eosinophilic esophagitis in real life: 10 years' experience with a focus on allergic management.
Allergol Immunopathol (Madr)
; 48(3): 244-250, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31813622
4.
Pilot Study of the Applicability, Usability, and Accuracy of the Nutricate© Online Application, a New Dietary Intake Assessment Tool for Managing Infant Cow's Milk Allergy.
Nutrients
; 15(4)2023 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36839403
5.
Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI): protocol for a phase 2a randomized controlled trial.
Front Med (Lausanne)
; 10: 1198173, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37448803
6.
Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy.
Allergy Asthma Clin Immunol
; 16: 25, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32328115
7.
Correction to: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy.
Allergy Asthma Clin Immunol
; 16: 38, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32477416
8.
Children with eosinophilic esophagitis in real life: 10 years' experience with a focus on allergic management
Allergol. immunopatol
; 48(3): 244-250, mayo-jun. 2020. graf, tab
Artículo
en Inglés
| IBECS (España) | ID: ibc-192026
Resultados
1 -
8
de 8
1
Próxima >
>>